Physician profile
Brittnie Smith
NPI 1740537562
$3,782.26
in general payments reported to CMS, 2019-2025
23 companies · $778 in 2025
The $778 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $530 · 2022: $1,036 · 2023: $824 · 2024: $614 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.87 |
| Education | $100.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,397.64 | 2021-2025 | Interstim |
| Teleflex LLC | $421.95 | 2022-2024 | Urolift |
| Sumitomo Pharma America, INC. | $313.26 | 2023-2025 | Orgovyx, Gemtesa |
| Abbvie INC. | $273.66 | 2021-2024 | |
| Janssen Biotech, INC. | $218.39 | 2021-2025 | Erleada |
| Astellas Pharma US INC | $178.84 | 2021-2024 | Myrbetriq |
| Procept Biorobotics Corporation | $173.26 | 2023 | Aquabeam Robotic System |
| Urogen Pharma, INC. | $132.97 | 2022-2025 | |
| Axonics, INC. | $128.50 | 2021-2023 | Axonics |
| Myovant Sciences INC. | $93.90 | 2022 | |
| Endo Pharmaceuticals INC. | $85.86 | 2021 | |
| Accord Healthcare, INC. | $73.58 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $48.40 | 2023-2025 | Imfinzi, Evusheld |
| Urovant Sciences INC | $37.56 | 2021-2022 | |
| Antares Pharma, INC. | $37.47 | 2021-2024 | Xyosted |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $29.83 | 2021 | |
| Blue Earth Diagnostics | $28.57 | 2021 | |
| Lantheus Medical Imaging, INC. | $24.63 | 2024 | |
| Merck Sharp & Dohme LLC | $18.74 | 2023 | Welireg, Lynparza, Keytruda |
| Verity Pharmaceuticals INC. | $17.96 | 2024 | Trelstar |
| Ferring Pharmaceuticals INC. | $17.71 | 2024 | Adstiladrin |
| Halozyme INC | $15.19 | 2023 | |
| Clarus Therapeutics INC. | $14.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittnie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.